The phase III MDP301 trial evaluated the vaginal microbicide gel PRO2000 against a placebo gel for safety and effectiveness in reducing the risk of HIV transmission. It is the largest vaginal microbicide trial to date and was conducted in six research centres in South Africa, Tanzania, Uganda and Zambia. The study found no evidence that the vaginal microbicide, PRO 2000, reduces the risk of HIV infection in women.
The MRC Clinical Trials Unit was involved in the design, co-ordination, data management, and analysis of the trial.
The Microbicides Development Programme (MDP) is a not-for-profit, African-European partnership, which was established to develop vaginal microbicides to reduce the risk of HIV infection in women. MDP is funded by the UK government through the Department for International Development (DFID) and the MRC, and managed jointly by Imperial College, London and the MRC Clinical Trials Unit.
For more information on the Microbicides Development Programme and the MDP301 trial results please visit the MDP website.